PC 111
Alternative Names: PC-111Latest Information Update: 25 Jul 2024
At a glance
- Originator PinCell
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Fas ligand protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pemphigus
Highest Development Phases
- Preclinical Pemphigus; Stevens-Johnson syndrome
Most Recent Events
- 25 Jul 2024 Preclinical development is ongoing Italy (Presentation in Pincell website, July 2024)
- 01 May 2023 Pincell has patent protection for PC 111 in World (Presentation in Pincell website, May 2023)
- 01 May 2023 Pincell has patents pending for PC 111 in USA (Presentation in Pincell website, May 2023)